Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
Beneficial effects of GLP-1RA in patients with obesity-related HFpEF and T2D
Mikhail Kosiborod, MD
Long-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
Alexander Fanaroff, MD
Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
Akshay S. Desai, MD
Preventive PCI versus optimal medical therapy only for vulnerable plaques
Marc Bonaca, MD
Loading...
We’re glad to see you’re enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.